Cutaneous Melanoma, Stage III
Oncology·MeSH: Melanoma
Prevalence
75.0 / 100K
Incidence
23.0 / 100K/yr
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 3(1)
Frequently asked questions
How many drugs are in development for Cutaneous Melanoma, Stage III?
BioSniper tracks 1 drug in development for Cutaneous Melanoma, Stage III across 1 company.
How many clinical trials target Cutaneous Melanoma, Stage III?
There are 1 clinical trial targeting Cutaneous Melanoma, Stage III tracked by BioSniper.
What is the prevalence of Cutaneous Melanoma, Stage III?
The estimated prevalence of Cutaneous Melanoma, Stage III is approximately 75.0 per 100,000 population.
Deep-dive into Cutaneous Melanoma, Stage III
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis